Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is limited. Our objective is to re...
Main Authors: | Inês Raposo, Andreia Bettencourt, Luiz Leite, Manuela Selores, Tiago Torres |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2019-03-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10728 |
Similar Items
-
Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
by: I. V. Rychkova, et al.
Published: (2019-08-01) -
Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01) -
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01) -
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018-10-01) -
Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)